China Draws a Line Around Its Biotech Crown Jewels

On October 16, China's Ministry of Commerce and Ministry of Science and Technology published a draft revision to the country's technology export catalogue that sent a clear message to the global biopharma industry: Beijing intends to keep ownership of its most valuable biotech platforms firmly within its borders. The proposal, which covers 40 technologies spanning artificial intelligence, biomedicine, and photovoltaics, would prohibit foreign entities from acquiring proprietary cell and gene therapy, small interfering RNA (siRNA), and pathogen gain-of-function platforms from Chinese companies. A public comment period runs through November 15, 2026.

The headline is striking. But the fine print tells a more nuanced story, and understanding the distinction between what is banned and what is not may matter more to the industry than the announcement itself.

What the Rule Actually Does

The draft defines a "platform" as a set of foundational technologies accumulated through long-term research and development that can support the creation of multiple drugs. Technologies developed for a single drug fall outside that definition. Under the proposed rules, foreign companies would be prohibited from acquiring outright ownership of these platforms. However, out-licensing agreements, joint research arrangements, and outsourced manufacturing services that retain platform ownership in China are explicitly excluded from the ban.

That carve-out is significant. According to local biopharma data intelligence provider PharmCube, only five of the 121 cross-border Chinese biopharma out-licensing deals completed through July 1 of this year involved an ownership transfer. The overwhelming majority of Western deals for Chinese biotech assets have involved licensing specific drugs or using a platform to identify new molecules, not acquiring the platform itself. In that sense, the proposed rule formalizes a distinction that the market had already largely been operating within.

Aaron Gu, a partner at Chinese law firm Han Kun specializing in healthcare and life sciences, described the published draft as "significantly better than market expectations." Earlier rumors circulating since May had suggested the government might target nearly all prominent modalities in Chinese biopharma business development, including multispecific antibodies, antibody-drug conjugates, and protein degraders. The final draft is considerably narrower.

The Deal That Would No Longer Be Possible

There is, however, at least one high-profile transaction that would likely not have cleared the bar under the new rules. AstraZeneca's $1 billion acquisition of Gracell Biotechnologies in late 2023, which transferred full ownership of the FasTCAR cell manufacturing platform, was celebrated at the time as the first full acquisition of a Chinese biotech by a major Western pharmaceutical company. Under the proposed catalogue revision, that kind of deal would be prohibited.

The rule also introduces an immediate operational change: interim pre-export registration requirements that took effect upon the announcement. Chinese companies must now register covered transactions through MOFCOM's technology-trade management system before completing them, even while the formal catalogue revision remains in draft. This applies to overseas ownership transfers, licensing of domestic technology for overseas use, and changes that place domestic technology under overseas ownership or actual control.

A Mirror Image of Washington's Concerns

The timing of Beijing's move is not coincidental. It arrives as Washington has been intensifying its own scrutiny of US-China biopharma transactions. Congressional representatives recently introduced the Biotech Investment National Security Act, which would subject Chinese biopharma deals to additional review. The US Treasury Department, meanwhile, is working on rules that would likely preserve most licensing deals for Chinese drugs while tightening oversight of platform transfers.

Both governments appear to be converging on a similar conclusion from opposite directions: licensing is acceptable, but ownership transfer of foundational technology platforms is not. The result is a kind of informal bilateral consensus that preserves the flow of drug candidates across borders while drawing a harder line around the underlying technological infrastructure that generates them.

For the Chinese biopharma sector, which has seen foreign transactions in its assets reach $120 billion as of August 2026, a 36 percent jump year over year, the stakes are considerable. The government's stated rationale is to prevent Chinese companies from selling the "engine" that produces innovation, even as they continue to profit from licensing the vehicles it creates. A senior Chinese biopharma executive put it plainly in an earlier interview: "What authorities don't want to see is someone taking China's resources to build a great R&D engine, only to sell the entire company overseas."

What It Means for Western Dealmakers

For US and European companies that have been building pipelines through Chinese licensing partnerships, the practical impact of the draft rule is likely modest in the near term. The structure of most existing deals already aligns with what the proposed rules would permit. The more meaningful shift is psychological and strategic: Western companies now have formal confirmation that full platform acquisitions of the Gracell variety are off the table, and that any future deal involving novel target discovery technologies will require regulatory approval rather than simple notification.

The broader implication is that the era of relatively unconstrained cross-border biotech dealmaking between the US and China is giving way to a more managed, more scrutinized, and more explicitly geopolitical framework. Both sides are drawing maps of what they consider sovereign territory in the life sciences. The licensing lanes remain open. The ownership roads are being gated. For an industry that has spent the past several years building pipelines on the assumption that Chinese innovation could flow freely westward, that distinction is worth understanding precisely.